PURPOSE: There is evidence for a direct role of quantitative gene expression deregulation in mantle-cell lymphoma (MCL) pathogenesis. Our aim was to investigate gene expression associations with other pathogenic factors and the significance of gene expression in a multivariate survival analysis. PATIENTS AND METHODS: Quantitative expression of 20 genes of potential relevance for MCL prognosis and pathogenesis were analyzed using real-time reverse transcriptase polymerase chain reaction and correlated with clinical and genetic factors, tumor morphology, and Ki-67 index in 65 MCL samples. RESULTS: Genomic losses at the loci of TP53, RB1, and P16 were associated with reduced transcript levels of the respective genes, indicating a gene-dosage effect as the pathomechanism. Analysis of gene expression correlations between the candidate genes revealed a separation into two clusters, one dominated by proliferation activators, another by proliferation inhibitors and regulators of apoptosis. Whereas only weak associations were identified between gene expression and clinical parameters or blastoid morphology, several genes were correlated closely with the Ki-67 index, including the short CCND1 variant (positive correlation) and RB1, ATM, P27, and BMI (negative correlation). In multivariate survival analysis, expression levels of MYC, MDM2, EZH2, and CCND1 were the strongest prognostic factors independently of tumor proliferation and clinical factors. CONCLUSION: These results indicate a pathogenic contribution of several gene transcript levels to the biology and clinical course of MCL. Genes can be differentiated into factors contributing to proliferation deregulation, either by enhancement or loss of inhibition, and proliferation-independent factors potentially contributing to MCL pathogenesis by apoptosis impairment.
PURPOSE: There is evidence for a direct role of quantitative gene expression deregulation in mantle-cell lymphoma (MCL) pathogenesis. Our aim was to investigate gene expression associations with other pathogenic factors and the significance of gene expression in a multivariate survival analysis. PATIENTS AND METHODS: Quantitative expression of 20 genes of potential relevance for MCL prognosis and pathogenesis were analyzed using real-time reverse transcriptase polymerase chain reaction and correlated with clinical and genetic factors, tumor morphology, and Ki-67 index in 65 MCL samples. RESULTS: Genomic losses at the loci of TP53, RB1, and P16 were associated with reduced transcript levels of the respective genes, indicating a gene-dosage effect as the pathomechanism. Analysis of gene expression correlations between the candidate genes revealed a separation into two clusters, one dominated by proliferation activators, another by proliferation inhibitors and regulators of apoptosis. Whereas only weak associations were identified between gene expression and clinical parameters or blastoid morphology, several genes were correlated closely with the Ki-67 index, including the short CCND1 variant (positive correlation) and RB1, ATM, P27, and BMI (negative correlation). In multivariate survival analysis, expression levels of MYC, MDM2, EZH2, and CCND1 were the strongest prognostic factors independently of tumor proliferation and clinical factors. CONCLUSION: These results indicate a pathogenic contribution of several gene transcript levels to the biology and clinical course of MCL. Genes can be differentiated into factors contributing to proliferation deregulation, either by enhancement or loss of inhibition, and proliferation-independent factors potentially contributing to MCL pathogenesis by apoptosis impairment.
Authors: Katrin Tiemann; Jessica V Alluin; Anja Honegger; Pritsana Chomchan; Shikha Gaur; Yen Yun; Stephen J Forman; John J Rossi; Robert W Chen Journal: Leuk Lymphoma Date: 2011-07-12
Authors: Warren Fiskus; Rekha Rao; Ramesh Balusu; Siddhartha Ganguly; Jianguo Tao; Eduardo Sotomayor; Uma Mudunuru; Jacqueline E Smith; Stacey L Hembruff; Peter Atadja; Victor E Marquez; Kapil Bhalla Journal: Clin Cancer Res Date: 2012-08-29 Impact factor: 12.531
Authors: David W Scott; Pau Abrisqueta; George W Wright; Graham W Slack; Anja Mottok; Diego Villa; Pedro Jares; Hilka Rauert-Wunderlich; Cristina Royo; Guillem Clot; Magda Pinyol; Merrill Boyle; Fong Chun Chan; Rita M Braziel; Wing C Chan; Dennis D Weisenburger; James R Cook; Timothy C Greiner; Kai Fu; German Ott; Jan Delabie; Erlend B Smeland; Harald Holte; Elaine S Jaffe; Christian Steidl; Joseph M Connors; Randy D Gascoyne; Andreas Rosenwald; Louis M Staudt; Elias Campo; Lisa M Rimsza Journal: J Clin Oncol Date: 2017-03-14 Impact factor: 44.544
Authors: Chris T Williamson; Huong Muzik; Ali G Turhan; Alberto Zamò; Mark J O'Connor; D Gwyn Bebb; Susan P Lees-Miller Journal: Mol Cancer Ther Date: 2010-02-02 Impact factor: 6.261
Authors: Matthew J Oberley; Saurabh A Rajguru; Chong Zhang; Kyungmann Kim; Gene R Shaw; Kreg M Grindle; Brad S Kahl; Craig Kanugh; Jennifer Laffin; David T Yang Journal: Histopathology Date: 2013-08-08 Impact factor: 5.087
Authors: Alba Navarro; Guillem Clot; Miriam Prieto; Cristina Royo; Maria Carmela Vegliante; Virginia Amador; Elena Hartmann; Itziar Salaverria; Sílvia Beà; Jose Ignacio Martín-Subero; Andreas Rosenwald; German Ott; Adrian Wiestner; Wyndham H Wilson; Elías Campo; Luis Hernández Journal: Clin Cancer Res Date: 2013-05-02 Impact factor: 12.531
Authors: Eric D Hsi; Sin-Ho Jung; Raymond Lai; Jeffrey L Johnson; James R Cook; Dan Jones; Sven Devos; Bruce D Cheson; Lloyd E Damon; Jonathan Said Journal: Leuk Lymphoma Date: 2008-11